Stocks in play: iCo Therapeutics
Reported the successful conclusion of pre-clinical studies involving its lead oral Amphotericin B candidate, including compelling safety data from its pivotal 14-day GLP (Good Laboratory Practices compliant) toxicology study. iCo Therapeutics